The Drug Utilization Review Board Reviewed the Following New Drugs Classes on February 7, 2017

The Georgia Medicaid Fee-for-Service Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health’s (DCH) final decisions on the following new drug class reviews for the Georgia Medicaid Fee-for-Service Preferred Drug List (PDL). New drugs and drugs with a recommendation for change in PDL status are highlighted below. The recommendations on all other drugs remained the same as the current PDL status, which is located at http://dch.georgia.gov/preferred-drug-lists.

Duchenne Muscular Dystrophy

The DUR Board provided No Recommendation at this time for Exondys 51 (Intravenous) Injection.

von Willebrand Factor Products

The DUR Board recommended Non-Preferred status with Prior Authorization for Vonvendi (Intravenous) Injection.

Ophthalmic Immunomodulators

The DUR Board recommended Non-Preferred status with Prior Authorization for Xiidra (Ophthalmic) Solution.

Gout Agents

The DUR Board recommended Non-Preferred status with Prior Authorization for Zurampic (Oral) Tablet.